Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.57 |
| ▸ | MEN1 | O00255 | 4/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | CRHBP | P24387 | 1/20 | 0.50 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6940890 | 0.92 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL6940685 | 0.92 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL6941498 | 0.89 | MAPT (0.62) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL7424412 | 0.88 | MAPT (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL6942791 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL6939398 | 0.84 | ALDH1A1 (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL7564040 | 0.84 | MAPT (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL7564054 | 0.84 | MAPT (0.61) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL6941788 | 0.83 | ALDH1A1 (0.63) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 | |
| SCHEMBL7426035 | 0.83 | ALDH1A1 (0.58) | ALDH1A1MAPTSMN1; SMN2HPGDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1080069-B1 | ANTHRANILIC ACID DERIVATIVES AS INHIBITORS OF THE CGMP-PHOSPHODIESTERASE | FUJISAWA PHARMACEUTICAL CO (JP) | 2003-03-19 | — | — | EP | disclosed |
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6384080-B1 | TREATMENT AND/OR PREVENTION OF CERTAIN CARDIOVASCULAR DISORDERS, UROGENITAL DISORDERS, RESPIRATORY SYSTEM DISORDERS, DISORDERS OF GUT MOTILITY, SEXUAL DISORDERS, DIABETIC COMPLICATIONS, URTICARIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193614-A1 | Anthranilic acid derivatives as inhibitors of the CGMP-phosphodiesterase | PDE3A, PDE2A, PDE5A | ALDH1A1 253/4885MAPT 4706/4885SMN1; SMN2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.